AX 1604 - Axim Biotech

Drug Profile

AX 1604 - Axim Biotech

Alternative Names: AX-1604

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator Axim Biotech
  • Class Antipsychotics; Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Psychotic disorders

Most Recent Events

  • 16 Nov 2016 Axim Biotech receives patent allowance for cannabinoid-containing controlled-release chewing gum products in USA
  • 09 Nov 2016 Phase-I clinical trials in Psychotic disorders in USA (Buccal) before November 2016 (Axim Biotech pipeline, November 2016)
  • 09 Nov 2016 Axim Biotech announces intention to submit NDA in 2021 (Axim Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top